TABLE 1.
Glycan No. | Designation | CI-MPRa | Dom1–3-His | Dom5-His | Dom5–9 | Dom9His | Dom7–11 |
---|---|---|---|---|---|---|---|
9 | GPM6 | 6.2 × 10−10 | DNBb | 8.7 × 10−6 | 3.7 × 10−9 | DNB | DNB |
10 | 2(GP)M6 | 8.0 × 10−11 | DNB | 6.9 × 10−6 | 3.3 × 10−9 | 1.1 × 10−6 | 5.48 × 10−7 |
11 | GPM7(3) | 5.9 × 10−9 | DNB | 1.8 × 10−5 | 8.9 × 10−9 | DNB | DNB |
12 | GPM7(2) | >5.8 × 10−8 | DNB | DNB | >2.8 × 10−7 | DNB | DNB |
13 | 2(GP)M7(1)+(3) | 6.0 × 10−11 | DNB | 4.3 × 10−6 | 3.0 × 10−9 | DNB | DNB |
14 | GPM8(1) | 1.1 × 10−10 | DNB | 1.6 × 10−5 | 4.0 × 10−9 | DNB | DNB |
15 | GPM9 | 1.9 × 10−10 | DNB | 1.8 × 10−5 | 5.7 × 10−9 | DNB | DNB |
16 | 2(GP)M9 | 7.0 × 10−11 | DNB | 4.8 × 10−6 | 4.1 × 10−9 | DNB | DNB |
17 | PM6 | 7.0 × 10−11 | 1.1 × 10−7 | DNB | 1.4 × 10−8 | 6.6 × 10−8 | 5.5 × 10−8 |
18 | 2(P)M6 | 8.0 × 10−11 | 1.0 × 10−7 | DNB | 1.9 × 10−8 | 5.7 × 10−8 | 6.7 × 10−8 |
19 | PM7(3) | 9.0 × 10−11 | 1.3 × 10−7 | DNB | 2.5 × 10−8 | 6.8 × 10−8 | 8.1 × 10−8 |
20 | PM7(2) | 5.2 × 10−9 | >1.0 × 10−6 | DNB | >2.8 × 10−7 | >1.2 × 10−6 | >6.0 × 10−7 |
21 | 2(P)M7(1)+(3) | 8.0 × 10−11 | 8.7 × 10−8 | DNB | 1.7 × 10−8 | 5.5 × 10−8 | 4.8 × 10−8 |
22 | PM8(1) | 1.7 × 10−10 | >1.0 × 10−6 | DNB | 4.2 × 10−8 | 1.9 × 10−7 | 2.6 × 10−7 |
23 | PM9 | 1.2 × 10−10 | >1.0 × 10−6 | DNB | 5.7 × 10−8 | 1.5 × 10−7 | 2.7 × 10−7 |
24 | 2(P)M9 | 8.0 × 10−11 | 1.4 × 10−7 | DNB | 2.6 × 10−8 | 5.2 × 10−8 | 8.6 × 10−8 |
a The half-maximal binding concentration (μg/ml) for each MPR construct was estimated from graphs of the data shown in supplemental Fig. S1. The estimated Kd value are shown in molar concentrations using the following molecular mass assignments: sCI-MPR (dimer), 520,000 Da; Dom1–3His, 50,000 Da; Dom5His, 21,000 Da; Dom5–9, 90,000 Da; Dom9His (dimer), 42,000 Da; and Dom7–11, 84,000 Da.
b DNB, did not bind.